- $1.10bn
- $1.13bn
- $202.09m
- 53
- 16
- 78
- 47
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 34.9 | 56.5 | 99.7 | 149 | 202 |
Cost of Revenue | |||||
Gross Profit | 26.9 | 38.2 | 56.1 | 92.7 | 141 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 134 | 210 | 145 | 214 | 251 |
Operating Profit | -98.9 | -153 | -45.4 | -65.3 | -49.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -105 | -163 | -46.8 | -74.3 | -61.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -90 | -163 | -46.8 | -74.4 | -61.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -90 | -163 | -46.8 | -74.4 | -61.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -90 | -163 | -46.8 | -74.4 | -61.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.09 | -3.21 | -1.18 | -1.26 | -1.04 |